

Scientific Session NRG Oncology Research Review Agenda

Advancing Research. Improving Lives.™

Date: Friday, July 14, 2017
Start and End Time: 8:00 am – 10:00 am
Co-Chairs: Deborah W Bruner, PhD; Krishnansu Tewari, MD; Thomas B Julian, MD
Moderator: Elizabeth M Gore, MD

8:00 – 8:05 am	Welcome	Elizabeth M Gore, MD
8:05 – 8:15 am	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology NSABP B-28 and B-14	Norman Wolmark, MD
8:15 – 8:25 am	Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NRG Oncology NSABP B-31 Trial	Katherine Pogue-Geile, MD
8:25-8:30 am	Discussant	Wendy Woodward, MD
8:30-8:40 am	Questions	
8:40 – 8:50 am	Quality of life and symptoms in long-term survivors of colorectal cancer: Results from NRG Oncology NSABP protocol LTS-01	Hiroko Kunitake, MD
8:50 – 9:00 am	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129	William R Robinson, MD
9:00 – 9:10 am	Discussant	Patricia A Ganz, MD
9:10 – 9:20 am	Questions	
9:20 – 9:30 am	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG Oncology Gynecologic Oncology Group study	Angeles Secord, MD
9:30 – 9:35 am	Discussant	Amina Ahmed, MD
9:30– 9:40 am	Questions	
9:40 – 9:50 am	Closing Discussion	

Learning Objectives

Following this activity, participants will be better able to:

1. Discuss the prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen:
2. Describe the association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2-positive breast cancer.
3. Describe the results of quality of life analyses for long-term survivors of colorectal cancer and for patients with locally advanced head and neck cancer treated with chemoradiotherapy.
4. Discuss the issues related to the administration and completion of a chemotherapy regimen in elderly women with ovarian, primary peritoneal or fallopian tube cancer